Moderna (NASDAQ:MRNA) is progressing on efforts to resume revenue growth in 2025 — even as COVID-19 vaccine sales decline now that the virus is endemic versus a pandemic. During a presentation at the JP Morgan Healthcare Conference this week, Moderna CFO Jamey Mock noted that the company took a charge of $1.6 billion during the…
Moderna earnings miss in Q4 as COVID shot demand declines
Moderna (NASDAQ:MRNA) today reported fourth-quarter results that beat the Wall Street consensus on revenue but missed on earnings. Demand for the company’s COVID-19 vaccines is down, and there is surplus production capacity. Investors reacted by sending MRNA shares down more than 1% to $156.51 apiece in morning trading. Q4 2022 Q4 2021 Change Revenue $5.1…
Pfizer and Moderna seek FDA nod for omicron-adapted COVID boosters in children
Pfizer/BioNTech (NYSE:/PFE, Nasdaq BNTX) and Moderna (Nasdaq:MRNA) have both won emergency use authorizations in the U.S. for bivalent vaccine boosters based on BA.4/BA.5. Pfizer is aiming to win authorization to use its updated COVID-19 vaccine in children aged 5 through 11 years. Moderna has requested that FDA greenlight the use of its omicron booster in…
Young children in U.S. now eligible for COVID-19 vaccination
Some 18 months after adults became eligible for COVID-19 vaccines, children between 6 months and 5 years old can now be vaccinated in the U.S. FDA authorized the shots for young children on June 17, while CDC did so a day later. “The United States is now the first country in the world to offer safe…
Moderna’s new CFO leaves after former employer discloses investigation
Moderna (Nasdaq:MRNA) CFO Jorge Gomez is gone from his new job effective immediately, the COVID-19 vaccine maker said today. Cambridge, Massachusetts–based Moderna said the departure comes after Gomez’s former employer, Dentsply Sirona (Nasdaq:XRAY), announced an “ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a news release. Moderna did not say whether…
Moderna names former Merck exec as new chief commercial officer
COVID-19 vaccine developer Moderna (Nasdaq:MRNA) has named Arpa Garay as its chief commercial officer starting May 31, 2022. Garay spent more than 15 years at Merck & Co. (NYSE:MRK). In February, she was promoted to the post of chief marketing officer for Merck’s human health division. Garay also was a member of the company’s executive…
Developing nations shun AstraZeneca’s COVID-19 vaccine
A number of developing nations have refused tens of millions of doses of AstraZeneca’s COVID-19 vaccines, according to a report from Reuters. The countries had received doses of the AstraZeneca vaccine from the COVAX initiative, a global project that focuses on ensuring equitable access to COVID-19 vaccines. COVAX has distributed 1.4 billion shots to 144 nations…
FDA backs second COVID-19 vaccine booster for some Americans
FDA has authorized a second booster dose of COVID-19 vaccine for individuals who are immunocompromised or 50 and over. The expanded emergency use authorization applies to the vaccines from Pfizer (NYSE: Pfizer) and Moderna (Nasdaq: MRNA). Individuals interested in obtaining a second booster dose must wait at least four months after receiving the first booster dose.…
Countries in need will have access to Moderna COVID-19 vaccine tech
Moderna (Nasdaq:MRNA) announced four new initiatives within a global public health strategy for advancing mRNA vaccines. Cambridge, Massachusetts-based Moderna plans to expand its global public health portfolio, accelerate research in an effort to advance additional vaccines, expand its patent pledge to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income…
FDA fully approves Moderna’s COVID-19 vaccine
Moderna (NSDQ:MRNA) announced today that it received full FDA approval of the biologics license application for its COVID-19 vaccine. FDA’s approval for the company’s Spikevax mRNA COVID-19 vaccine covers the prevention of the virus in individuals aged 18 years or older. Moderna submitted for full FDA approval back in June 2021 and becomes the second…